Zomedica Corp. Form 4 shows 1.82M SARs granted to director

Rhea-AI Filing Summary

Zomedica Corp. (ZOMDF) reported a change in director equity holdings on a Form 4. On 11/17/2025, a director acquired a stock appreciation right covering 1,823,107 derivative securities at a conversion or exercise price of $0.10 per underlying share. The derivative security is linked to 1,823,107 shares of common stock, becomes exercisable on 11/16/2026, and expires on 11/16/2035. Following this transaction, the director beneficially owns 1,823,107 derivative securities with direct ownership reported.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MACLEOD CHRISTOPHER ROSS

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Appreciation Right	1,823,107	$0.00	--

Holdings After Transaction: Stock Appreciation Right — 1,823,107 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MACLEOD CHRISTOPHER ROSS

(Last) (First) (Middle)

1101 TECHNOLOGY DRIVE, STE 100

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ ZOMDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Right	$0.1	11/17/2025		A		1,823,107		11/16/2026	11/16/2035	Common	1,823,107	$0	1,823,107	D

Explanation of Responses:

	/s/ Christopher MacLeod	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Zomedica Corp. (ZOMDF) report in this Form 4 filing?

The filing reports that a director of Zomedica Corp. acquired a stock appreciation right linked to the companys common stock.

How many stock appreciation rights were reported for the ZOMDF director?

The director acquired 1,823,107 derivative securities in the form of a stock appreciation right, tied to 1,823,107 shares of common stock.

What is the exercise or conversion price of the Zomedica (ZOMDF) stock appreciation right?

The stock appreciation right has a conversion or exercise price of $0.10 per underlying share of common stock.

When do the reported Zomedica (ZOMDF) stock appreciation rights vest and expire?

The filing states that the stock appreciation right becomes exercisable on 11/16/2026 and has an expiration date of 11/16/2035.

How many derivative securities does the ZOMDF director beneficially own after this transaction?

After the reported transaction, the director beneficially owns 1,823,107 derivative securities related to Zomedica common stock.

Is the ownership of the reported Zomedica (ZOMDF) derivative securities direct or indirect?

The Form 4 indicates that the 1,823,107 derivative securities are held with direct (D) ownership by the reporting person.